key: cord-0699390-nbqukiqi
authors: Tanaka, Mototsugu; Mise, Naobumi
title: Need for evidence on long-term prognosis of PD+HD: a commentary
date: 2021-01-07
journal: BMC Nephrol
DOI: 10.1186/s12882-020-02212-x
sha: 677109a7f2b348a760f83305573b664f1c3bf8e7
doc_id: 699390
cord_uid: nbqukiqi

Combination therapy with peritoneal dialysis and hemodialysis (PD+HD) is an alternative dialysis method for patients with end-stage kidney disease (ESKD). The complementary use of once-weekly HD expedites to achieve adequate dialysis and enables to prolong PD duration. Although PD+HD has been widely employed among Japanese PD patients, it is much less common outside Japan. Clinical evidences are still not enough, especially in long-term prognosis and appropriate treatment duration, suitable patients, and generalizability. A retrospective cohort study by Chung et al. (BMC Nephrol 21:348, 2020) compared the risk of mortality and hospitalization between PD patients who were transferred to PD+HD and those who were transferred to HD in Taiwan. Because the mortality and hospitalization rates did not differ between the groups, the authors concluded that, PD+HD may be a rational and cost-effective treatment option. It should be noted that the effects of PD+HD on long-term prognosis are still unknown due to too-short PD+HD duration. However, the study identified the high-risk patient population and showed the generalizability of PD+HD. PD+HD is a treatment of choice in patients with ESKD who prefer PD lifestyles even after decline in residual kidney function.

Combination therapy with peritoneal dialysis and hemodialysis (PD+HD) has been widely used in Japan (Fig. 1) . Currently, one-fifth of Japanese PD patients are on PD+HD, and 87.9% of those are treated with 5 to 6 days of PD and once-weekly HD (Japanese Society for Dialysis Therapy, unpublished data), which is covered by the national health insurance as a maintenance dialysis. Since the complementary use of HD ameliorates underdialysis and overhydration and enables significant prolongation of PD, PD+HD is preferred by PD patients who wish to maintain PD lifestyles after decline in residual kidney function [1, 2] . In fact, health-related quality of life for PD+HD was close to that for PD but was better than HD in role and social functions [3] . In this cohort, hospitalization risk was similar between PD+HD and HD, although PD+HD may have a higher hospitalization risk of dialysis access-related complications than HD [4] . However, many of these findings were from low quality studies, and several important arguments, such as long-term prognosis and appropriate treatment duration, and suitable patients, have not been determined. The generalizability of PD+HD was also unclear, since there have been few reports from outside Japan so far.

Chung et al. recently reported a retrospective cohort study comparing the risk of mortality and hospitalization (including emergent hospital visits) between PD+HD group (transfer from PD to PD+HD) and HD group (transfer from PD to HD) using a health insurance database in Taiwan [5] . An intention-to-treat analysis revealed that both risks were similar between the two groups, although peritonitis was a strong risk factor for hospitalization in PD+HD. The authors concluded that PD+HD is a safe, rational, and may be a cost-effective treatment for patients with end-stage kidney disease (ESKD), and the larger number of patients and longer observation period than previous studies may strengthen the present study conclusion.

However, long-term prognostic effects of PD+HD have not been clarified yet. In the present study, about 58% of patients were transferred from PD+HD to HD within a year. Too-short PD+HD duration makes it difficult to understand the crude effects of the combined dialysis in a 12-year follow-up. In addition, it remains unclear whether patients with ESKD can be treated adequately with PD+HD for a long period. A multivariate analysis including PD+HD duration may help to understand the long-term prognostic impacts and appropriate treatment period of this combined modality.

Nevertheless, the present study provided an important finding that PD+HD had a similar prognosis to HD, which was compatible with a recent Japanese study [4] . The consistency of the results from different regions suggested the feasibility and generalizability of PD+HD. There may be some differences in health insurance policies and the treatment strategies for additional HD between Japan and Taiwan. While once-weekly HD is routinely performed in most Japanese PD+HD patients, the study showed that a half of PD+HD patients in Taiwan were treated with only two HD sessions per month, and in such patients, HD was sometimes used as a rescue treatment. This biweekly HD regimen of PD+ HD may increase the generalizability in developing countries.

The present study also suggested that PD+HD can be prescribed as an individualized, bridging dialysis modality. The flexibility may enable a smooth and appropriate transition of dialysis modality, and it may be of help during disastrous situations, such as recent COVID-19 pandemic [6] . On the other hand, dialysis access-related complications [4] and peritonitis [5] were risk factors of hospitalization for PD+HD, and technique survival rate was poor in those who required high ultrafiltration volume by additional HD [7] . It is necessary to identify suitable patients and establish the optimal indication for PD+HD.

In the present study, the authors proposed PD+HD as a part of an integrated dialysis care and mentioned that dialysis staff should be familiar with this combined modality. A patient-centered dialysis prescription by the shared decision-making is desired [8] , however, many patients are feeling that they had not been sufficiently explained about dialysis modalities at the start of dialysis [9] . An increased awareness of PD+HD would provide patients more treatment choices in the precision medicine era.

A recent study by Chung et al. suggested that mortality and hospitalization risks were similar between PD patients who were transferred to PD+HD and those who were transferred to HD in Taiwan [5] . However, the effects of PD+HD on long-term prognosis was unclear, since the treatment duration of PD+HD was too-short in the study. Nevertheless, this interesting paper provided several important findings. Firstly, PD+HD may be a safe, feasible, and flexible dialysis modality which is generalizable both in Japan and Taiwan. Secondary, patients with recent peritonitis were at a high risk of hospitalization. Clinicians and nurses should have a good understanding of PD+HD to apply precision medicine in clinical practice. For each modality, the frequency of treatment can be modified based on patient characteristics. PD+HD may be used as either a bridging therapy or a maintenance therapy. Complementary use of HD increases dialysis doses and fluid removal in PD patients after decline in residual kidney function. PD+HD may also allow "PDholiday" that mitigates excessive exposure to glucose dialysate. Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; PD+HD, combination therapy with peritoneal dialysis and hemodialysis

Combination therapy with peritoneal dialysis and hemodialysis

Clinical effects of combined therapy with peritoneal dialysis and hemodialysis

Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: a cross-sectional study

Hospitalization for Patients on Combination Therapy With Peritoneal Dialysis and Hemodialysis Compared With Hemodialysis

Is combined peritoneal dialysis and hemodialysis redundant? A nationwide study from Taiwan

Combined therapy using peritoneal dialysis and hemodialysis may increase the indications for peritoneal dialysis in the United States

Ultrafiltration volume by once-weekly hemodialysis is a predictor of technique survival of combination therapy with peritoneal dialysis and hemodialysis

Person-centered peritoneal dialysis prescription and the role of shared decision-making

Patient Perspectives on the Choice of Dialysis Modality: Results From the Empowering Patients on Choices for Renal Replacement Therapy (EPOCH-RRT) Study

Not applicable. 

Not applicable.Availability of data and materials Not applicable.Ethics approval and consent to participate Not applicable

Author details Received: 9 November 2020 Accepted: 14 December 2020